

TRANSCRANIAL MAGNETIC STIMULATION

Policy Number: BH727BCPTMS_112017

Effective Date: November, 2017

Table of Contents	Page
BENEFIT CONSIDERATIONS	1
COVERAGE RATIONALE	1
UTILIZATION MANAGEMENT CRITERIA	2
DESCRIPTION OF SERVICES	2
CLINICAL EVIDENCE	3
U.S. FOOD AND DRUG ADMINISTRATION	8
CENTERS FOR MEDICARE AND MEDICAID SERVICES	8
APPLICABLE CODES	8
REFERENCES	9
HISTORY/REVISION INFORMATION	11

Related Clinical Policies & Guidelines:

- Depressive Disorders
- Electroconvulsive Therapy

BENEFIT CONSIDERATIONS

Before using this policy, please check the member-specific benefit plan document and any federal or state mandates, if applicable.

COVERAGE RATIONALE

Transcranial magnetic stimulation is proven and medically necessary for the treatment of patients 18 years of age or older with a confirmed diagnosis of major depressive disorder when all of the following conditions are met:

- One of the following scenarios applies:
 - The patient's depression has not responded to at least four (4) prior antidepressant medication trials at or above the minimal effective dose and duration in the current episode.
 - The patient has a documented inability to tolerate psychopharmacologic agents as evidenced by trials of four such agents, from at least two different agent classes, with distinct side effects
 - The patient has a documented history of response to TMS in a previous depressive episode, as evidenced by a greater than 50% improvement on a standardized rating scale for depression symptoms
- A trial of an evidence-based psychotherapy known to be effective in the treatment of MDD of an adequate frequency and duration has been attempted without significant improvement in depressive symptoms as documented on a standardized rating scale for depression symptoms
- The member's current baseline depression measurement score has been documented using an evidence-based validated rating scale (e.g., BDI; HAM-D; MADRS)
- TMS treatment is provided using a device that is approved by the FDA for the treatment of major depressive disorder.
- TMS Treatment is prescribed and provided by, or under the supervision of, a psychiatrist trained in the use of the specific device. The TMS operator should be trained and certified to deliver rTMS including device operation, TMS coil targeting, and recognition and management of side effects. He or she should be trained as a first responder to a seizure and have basic life support training certification. (McClintock 2017).

Transcranial magnetic stimulation is unproven and not medically necessary for any of the following:

- Patients not meeting the above evidence-based coverage criteria
- Treatment of behavioral disorders other than major depressive disorder
- Maintenance therapy

Use of transcranial magnetic stimulation is contraindicated in the following populations, which could result in serious injury or death:

- Patients who have conductive, ferromagnetic, or other magnetic-sensitive metals implanted in their head within 30 cm of the treatment coil. Examples include metal plates, aneurysm coils, cochlear implants, ocular implants, deep brain stimulation devices, and stents.
- Patients who have active or inactive implants (including device leads), including deep brain stimulators, cochlear implants, and vagus nerve stimulators.
- Patients with psychoses or with psychiatric emergencies where a rapid clinical response is needed, such as marked physical deterioration, catatonia, or immediate suicide risk.

The safety and effectiveness of TMS therapy has not been established in the following patient populations or clinical conditions through a controlled clinical trial. The use of TMS in these patients is therefore unproven:

- Patients who are acutely suicidal.
- Patients with a history of substance abuse, eating disorder, or post-traumatic stress disorder whose symptoms are the primary contributors to the clinical presentation
- Patients with a history of or risk factors for seizures during TMS therapy
- Patients with vagus nerve stimulators or implants controlled by physiologic signals, including pacemakers, and implantable cardioverter defibrillators
- Patients who are pregnant or nursing
- TMS treatment for bipolar disorder, or psychotic disorder (including schizoaffective disorder and major depression with psychotic features), OCD, PTSD, Smoking cessation, , stroke, chronic pain, Alzheimer's disease and autism is considered investigational. There is insufficient evidence to support the use of TMS for these diagnoses.

UTILIZATION MANAGEMENT CRITERIA

Transcranial Magnetic Stimulation Admission Criteria

- see "*Common Criteria and Best Practices for All Levels of Care*":
<https://www.providerexpress.com/content/ope-provexpr/us/en/clinical-resources/guidelines-policies/locg.html>
AND
- The criteria from the [coverage rationale](#) section of this document are met
AND
- Suicide risk should be evaluated. Assessment of suicide risk should include the following:
 - The member's most current diagnoses;
 - Current suicidal ideation, plan, and means;
 - The history of suicidal behavior;
 - The nature of the current crisis or other unique issues that may have precipitated suicidal behavior;
 - Relevant familial factors, such as history of attempts, completion of suicide, and mental illness; if there is active suicidality, additional review may be warranted to evaluate whether TMS is the most appropriate treatment, or whether a more intensive treatment is indicated.
AND
- Prior to initiating treatment, the member's motor threshold (MT) is determined in order to provide an estimate of the magnetic field intensity, and to provide a head surface landmark to permit navigation to the treatment location.

Transcranial Magnetic Stimulation Continued Service Criteria

- see "*Common Criteria and Best Practices for All Levels of Care*":
<https://www.providerexpress.com/content/ope-provexpr/us/en/clinical-resources/guidelines-policies/locg.html>
- Motor Threshold (MT) should be initially established to ensure the most accurate treatment location.
- Treatment consists of a maximum of 30 sessions plus 6 tapering sessions.

Transcranial Magnetic Stimulation Discharge Planning and Criteria

- see "*Common Criteria and Best Practices for All Levels of Care*":
<https://www.providerexpress.com/content/ope-provexpr/us/en/clinical-resources/guidelines-policies/locg.html>
- Maintenance Therapy is considered not medically necessary by device manufacturers, and is not supported by the clinical evidence.

DESCRIPTION OF SERVICES

Transcranial Magnetic Stimulation (TMS) is a non-invasive technique using a device that has been approved by the Food and Drug Administration (FDA) to apply brief magnetic pulses to the brain for the treatment of major depressive disorder. The pulses are administered by passing currents through an electromagnetic coil placed adjacent to the

patient's scalp. The pulses induce an electrical field in the brain tissue, activating neurons in the targeted brain structure. By stimulating areas of the brain, the goal is to lessen the duration or severity of depressive episodes. TMS is typically applied daily in subjects with major depressive disorder who have failed previous antidepressant trials in the current episode.

CLINICAL EVIDENCE

Summary of Clinical Evidence

The results from a majority of studies, including multicenter randomized controlled trials, support the hypothesis that treatment with TMS is superior to sham TMS for the treatment of major depressive disorder. There is also growing research as to the durability of TMS treatment for this population, though the possible influence of concurrent antidepressant use in many study designs continues to pose a methodological limitation. FDA-approved TMS devices can be administered safely when treatment is provided under proper supervision and with adherence to the appropriate therapy manual. There is a need for conclusive evidence from controlled trials on the benefit of maintenance TMS therapy, such as when compared to maintenance antidepressant use. TMS has not been demonstrated to be equivalent in efficacy when compared to ECT for the treatment of major depressive disorder. Patients who are candidates for ECT and instead receive TMS likely do so because TMS is regarded as less invasive.

Clinical Trials

Yip and colleagues (2017) conducted a double-blind, placebo-controlled continuation TMS study to examine the response among acute-phase non-responders of deep repetitive transcranial magnetic stimulation (dTMS) monotherapy for depression. Participants were medication-free outpatients with a primary diagnosis of Major Depressive Disorder, single or recurrent episode, Clinical Global Impressions-Severity rating >4, and total score on the Hamilton Depression Rating Scale >20 initially. For this analysis, 33 participants that had received active treatment in a blinded fashion, but did not respond (>50% decrease in HDRS-21 total score relative to baseline) after 20 treatments were selected. Treatment included once daily dTMS, 5 days per week, for 20 minutes per session. Following the initial treatment (acute phase), the continuation phase consisted of twice-weekly dTMS sessions for up to 12 weeks. Results indicate that 61% of non-responders did respond to treatment after 4 weeks of daily dTMS treatment. In addition, 73% of participants were able to achieve responder status at least once, and 64% were able to achieve remission status at some point during continuation. The authors conclude that a significant number of non-responders to dTMS treatment can eventually respond to continued treatment. They further conclude that these results support the treatment beyond the acute treatment course for dTMS non-responders.

Haesebaert and colleagues (2016) conducted a 3-arm open-label study to investigate the clinical efficacy of repetitive transcranial magnetic stimulation (rTMS), venlafaxine, or a combination of both treatments as a maintenance treatment in patients with treatment-resistant depression (TRD). The study included 66 patients (of which 45 were remitters) who responded to rTMS (n = 25), venlafaxine (n = 22), or a combination of both treatments (n = 19). The patients continued to receive the respective treatment as a maintenance treatment over a 12-month period. Maintenance rTMS was delivered twice per week for the first month, once per week for the next two months, and once every two weeks for the remaining nine months. Venlafaxine was maintained at the dose that induced a clinical response (either 150mg/day or 225mg/day). At month 12, a total of 36 patients had been lost to follow-up. Results found that after 12 months of follow-up, there was no difference between the three groups in terms of rates of remitters or rates of patients who had not relapsed. The authors conclude that the three maintenance approaches exhibited similar efficacies in relapse prevention and maintenance of remission in patients with TRD. The authors note several limitations of the study, including the open-label observational design, without control group or placebo condition. Additionally, approximately half of the sample size of patients was ultimately lost to follow-up.

Philip and colleagues (2016) conducted a pilot feasibility study investigating 12-month outcomes of two maintenance TMS approaches. After an acute treatment phase consisting of 30 sessions of TMS (5 days per week for 6 weeks plus a three-week taper), patients who met study-defined response criteria (HAMD17 total score < 15 and more than 25% improvement in total score HAMD17 compared with baseline) were randomized into a maintenance phase. Patients were randomized to either (1) a single TMS session once every four weeks; or (2) observation only at each follow-up visit. All maintenance treatments were delivered open-label. Symptoms were assessed at monthly follow-up visits, and any patient meeting criteria for symptom recurrence (HAMD17 > 16 and > 25% worsening from HAMD17 score at entry into maintenance phase) received reintroduction TMS. All patients were antidepressant-free throughout the maintenance phase. A total of 67 patients were enrolled, with 49 (73%) completing acute treatment and randomized for the maintenance phase (23 into the TMS sessions and 26 into the observation only groups, respectively). Odds of achieving remission in the acute phase did not differ between groups. Of the 49 randomized patients, sixteen (33%) completed all 53 weeks of the study. The group randomized to TMS sessions had nonsignificantly longer time to first TMS reintroduction (91 vs. 77 days). The authors conclude that maintaining treatment-resistant depressed patients off medications with periodic TMS appears feasible in some cases. The authors note that interpretations should be tempered by consideration of the population studied, the relatively limited sample size, attrition rate, and open-label

design. They further note that the results indicate a maintenance TMS schedule of only one treatment per month is not sufficient to prevent return of depressive symptoms within the year.

Levkovitz and colleagues (2015) conducted a multi-center, double blind, controlled study evaluating clinical outcomes of dTMS for up to 4 months. At 20 sites, a total of 212 outpatients who had failed 1-4 antidepressant treatments within the current depressive episode were enrolled. Eligible subjects were aged 22-68 with DSM-IV diagnosed major depressive disorder, with duration of current episode at least one month but no more than 7 years. Subjects were required to have a HDRS-21 score of at least 20 at screening visit. Patients were randomly assigned to undergo dTMS using either H-coil or sham TMS, applied as a monotherapy after patients had tapered off antidepressant medications. Patients received daily weekday treatments at motor threshold (MT) 120% for 4 weeks acutely, then biweekly for an additional 12 weeks. Response was defined as a reduction of at least 50% in the total HDRS-21 score at week 5 compared to baseline, and remission was defined by a total HDRS-21 score < 10 at week 5. Response rates were 38.4% for dTMS vs. 21.4% for sham TMS. Remission rates were 32.6% and 14.6% for dTMS and sham TMS, respectively. The majority of patients achieving remission at the primary endpoint did not relapse until the end of the study. A total of 8 serious adverse events were reported in 7 subjects. One of the events, a seizure, was considered to be device-related and the event was reported to the FDA. Differences between active and sham treatment were stable during the 12-week maintenance treatment phase and were also observed in patients with higher degrees of treatment-resistance. The authors highlight the importance of adequate intensity (MT 120%) when training operators to use this system for antidepressant treatment.

Dunner and colleagues (2014) assessed a subset (n = 257) of patients from a previous acute efficacy TMS treatment outcomes study (Carpenter, et al 2012). This subset of patients completed their acute treatment and then, regardless of outcome, agreed to enroll in a 12-month long-term follow-up phase. Efficacy measures included the CGI-S, the IDS-SR, and the PHQ-9. A total of 205 patients completed outcome evaluations through 12 months. Of the 120 patients who were either responders or remitters after acute treatment, seventy-five (62.5%) continued to meet response criteria at all measured time points (3 mo, 6 mo, 9 mo, and 12 mo). Approximately one-third of patients received TMS reintroduction. Patients who received clinical benefit from TMS were significantly more likely to receive TMS reintroduction and were also significantly more likely to experience subsequent clinical benefit from reintroduction treatment. TMS reintroduction was seen in 15/77 (19.5%), 19/59 (32.2%), 27/44 (61.4%), and 32/76 (42.1%) of IDS-SR nonresponders, partial responders, responders, and remitters, respectively. The authors note limitations of no concurrent control population, and a lack of exploration on the influence of concomitant treatments, including the role of TMS reintroduction.

Harel and colleagues (2014) examined the safety and feasibility of deep TMS (dTMS) continuation treatment for major depressive disorder in 29 patients over the course of 18 weeks, following 4 weeks of acute treatment. The 22-week study was divided into three phases: an acute phase of 4 weeks in which daily sessions were conducted, for a total of 20 sessions; "continuation treatment I" of 8 weeks in which sessions were conducted twice a week for a total of 16 sessions; and "continuation treatment II" of 10 weeks, in which sessions were conducted once a week. Response was defined as > 50% decrease from baseline in HDRS score and remission as < 10 score on the HDRS. Relapse was defined as > 18 score on the HDRS for two consecutive weeks. Subjects were aged 18-65 and had a DSM-IV diagnosis of major depressive disorder. Participants also had a score of > 20 on the HDRS-21 at screening, and had either failed at least one adequate pharmacological trial during the current episode or had intolerance to two antidepressants. Twenty-six of the 29 patients completed the acute phase of treatment. Twelve (46.2%) of the subjects completing the acute treatment phase showed a significant response. Ten of the 26 subjects dropped out by the end of "continuation treatment I". A total of 15 subjects completed the full length of the continuation phase. As this study was an open study with a small sample size and add-on design, the authors note it was not possible to rule out a possible placebo effect and expectancy bias, as well as improvement from result of other factors. Another limitation was a high dropout rate, perhaps partly due to the relative length of the study. The authors conclude that future studies should use a sham controlled randomized design with a large number of patients to further assess the efficacy of dTMS in the treatment of MDD.

Carpenter and colleagues (2012) conducted a naturalistic, observational study to summarize outcomes experienced by a large population of depressed patients treated with TMS therapy in 42 clinical practice settings. A total of 339 patients were screened, leading to a final study population of 307. The study design permitted patients to continue concurrent psychiatric medications during TMS treatment. Outcome assessments were obtained at baseline, week 2, and week 6 in cases where the acute course of TMS extended beyond 6 weeks. Efficacy measures included the CGI-S, IDS-SR and the PHQ-9. For the CGI-S (primary outcome measure), response was defined as achieving an endpoint rating of 3 or less, while remission was defined as achieving an endpoint of 2 or 1. The average number of overall antidepressant treatment attempts in the current episode was 3.6, with a range of 0-21. The average number of adequate antidepressant treatments in the current episode was 2.5, with a range of 0-14. The average number of TMS sessions across the acute phase was 28.3 (range: 2-94). A significant change in CGI-S from baseline to end of treatment was found. Clinician-assessed response rate was 58% and remission rate was 37.1%. Patients who had failed a minimum of one adequate antidepressant trial were as likely to be TMS responders as those who had failed

two or more trials in the current episode. One case of seizure induction was reported. The authors conclude that observed clinical response and adherence rates in this naturalistic study were similar to those reported in open-label clinical trials in research study populations.

Mantovani and colleagues (2012) presented long-term follow-up of patients who were remitters from an acute double-blind controlled trial of TMS (George, et al 2010; n = 18) or from an open-label extension in patients who did not respond to the acute trial (McDonald, et al 2011; n = 43). Subjects were followed for 6 months, but retention from 3 to 6 months was too low (n = 20) to allow meaningful analysis. As a result, the authors chose to report the 3-month follow-up data. Relapse was the primary outcome and defined as HDRS-24 > 20. Of the 61 remitters in the acute trials, five entered naturalistic follow-up and 50 entered a TMS taper phase (three sessions the first 2 weeks, two sessions the second 2 weeks). A total of 32 patients completed the TMS taper and 1-, 2-, and 3-month follow-ups. At 3-month follow-up, 29 of the 50 (58%) were classified as in remission (HDRS-24 < 10), two of 50 (4%) were partial responders, and one of 50 (2%) met criteria for relapse. During the entire 3-month follow-up, five of the 37 patients relapsed (13.5%), with four of these patients regaining remission by the end of the study. The authors conclude that most patients experience persistence of benefit from TMS followed by pharmacotherapy or no medication, though they acknowledge that longer follow-up, lower drop-out rates, and more rigorous studies are needed to explore the true long-term durability of remission produced by TMS.

McDonald and colleagues (2011) conducted an open-label follow up to a larger controlled trial (George, et al 2010), first identifying those patients who failed to meet minimal response criteria in the controlled study, and then enrolling these individuals in treatment for an additional 3-6 weeks. Patients who failed to remit using fast TMS over the left dorsolateral prefrontal cortex (10 HZ @ 120% of motor threshold) could switch to slow right TMS (1 HZ @ 120% of motor threshold) for up to 4 additional weeks. The final outcome measure was remission, defined as a HAM-D score of < 3 or two consecutive HAM-D scores less than 10. Results found that 43 of the 141 patients (30.5%) who enrolled in the open phase study eventually met criteria for remission. Of the patients who failed fast left TMS, 26% remitted during slow right treatment. The authors conclude that the total number of TMS stimulations needed to achieve remission in treatment-resistant depression may be higher than is used in most studies. Noted is that the results of the study are limited by the open label trial.

Isserles and colleagues (2011) assessed the H1 deep TMS (dTMS) coil as an add-on to antidepressant medication in treating patients with major depression. The study enrolled 57 patients for 4 weeks of daily 20Hz stimulation sessions, and an additional 4 weekly sessions as a maintenance phase. Main entry criteria included a diagnosis of non-psychotic MDD with HDRS-24 score of > 21. Patients also had to have failed at least two antidepressant medications and been free from known TMS risk factors. Efficacy analyses were performed on 46 patients who had a baseline measurement and at least two additional weekly assessments (i.e., received at least 10 sessions of dTMS treatment). Response rate was defined as a decrease of at least 50% in the HDRS-24 score, and remission rate defined as a HDRS-24 score less than or equal to 10. Overall, treatment was reported as easy to tolerate, and most patients suffered no side effects nor complained of significant discomfort. Fifteen patients withdrew consent during the daily treatment phase. One patient suffered a short tonic-clonic generalized seizure during the second treatment session and was removed from the study. Overall, 21 of the 46 patients (46%) achieved response criterion, and 13 (28%) achieved remission criterion by the end of the daily treatment phase. Following the daily phase, 11 out of the 13 remitters continued to the four week maintenance phase. One patient left the study after 2 weeks of maintenance treatment, with the other 10 remitters concluding this phase and preserving remission criteria. The authors conclude that the positive results warrant a wider study that will include a sham control arm to confirm dTMS efficacy for resistant depression.

Janicak and colleagues (2010) assessed the durability of antidepressant effect after acute response to TMS in patients with MDD using protocol-specified maintenance antidepressant monotherapy. Using the randomized trial examining the acute efficacy and safety of TMS (O'Reardon, et al 2007) and a 6-week open trial of TMS (Avery, et al 2008), patients who met criteria for partial response (i.e., > 25% decrease from baseline on the HAM-D17) were followed for 24 weeks in a naturalistic follow-up study examining the long-term durability of TMS. During this durability study, TMS was readministered if patients met specified criteria for symptom worsening (i.e., a change of at least one point on the CGI-S scale for 2 consecutive weeks). Relapse was the primary outcome measure. A total of 1142 patients achieved at least partial response from either of the prior two trials, and a total of 99 patients who successfully transitioned from active TMS to maintenance antidepressant monotherapy agreed to follow-up for the additional 24 weeks. Thirty-eight patients (38.4%) had symptom worsening and received reintroduction TMS. Ten of the 99 patients relapsed. Safety and tolerability were similar to acute TMS monotherapy. The authors suggest that the therapeutic effects of TMS are durable and that TMS may be successfully used as an intermittent rescue strategy to preclude impending relapse. They note that limitations include a lack of a controlled comparison.

George and colleagues (2010) conducted a sham-controlled, randomized trial to test whether daily left prefrontal rTMS safely and effectively treats major depressive disorder. The study was conducted at 4 U.S. sites, and included a 2-week no-treatment lead-in phase, a 3-week fixed-treatment phase (delivered daily on weekdays), and a variable 3-week extension for clinical improvers. Randomization of 199 patients to active and sham conditions was based on

randomized permuted blocks stratified by site and higher or lower treatment resistance. Patients not showing sufficient improvement (< 30% drop from baseline in HAM-D score) at the end of the fixed 3-week period were discontinued from phase 1 and crossed over to open treatment (phase 2) without unmasking original assignment. If patients improved sufficiently (i.e., > 30% reduction in HAM-D score), treatment was continued for up to 3 additional weeks, with HAM-D assessments performed twice weekly. Antidepressant medication was started after the 3-week taper period. A total of 190 patients composed the intention-to-treat sample, with current average treatment resistance of 1.5 failed research-quality adequate treatment trials, and a range of 0-6 failed trials. There was a significant effect of treatment in the 190 patients, with 18 remitters (14.1% in the active arm and 5.1% in the sham arm). Five patients discontinued study participation because of adverse events, all of whom were receiving active TMS. No seizures or suicides occurred. In the open-label follow-up, 30.2% of originally active and 29.6% of sham patients remitted. The authors conclude that high-intensity rTMS for at least 3 weeks was significantly more likely than sham rTMS to induce remission in antidepressant medication-free patients with moderately treatment-resistant unipolar major depression. The authors do note several limitations to the study, including failure to enroll the projected 240 individuals suggested by the initial power analysis. Treaters were also able to guess randomization assignment better than chance. Although the treatment effect was statistically significant on a clinically meaningful variable (remission), the authors point out that the overall number of remitters and responders was less than one would like with a treatment requiring daily intervention for 3 weeks or more. The authors anticipate greater rates of overall response and remission if the TMS were delivered in combination with pharmacotherapy.

Janicak and colleagues (2008) examined comprehensive acute and long-term safety data obtained from 3 sequentially conducted studies of TMS. The first study was a large randomized, multisite, double-blind comparison of active TMS vs. sham TMS (O'Reardon, et al 2007). The second study (Avery, et al 2008) was a 6-week, open-label, acute efficacy study of TMS monotherapy available to all enrolled subjects whose depression had not responded sufficiently during the double blind-study. The third study (unpublished data, 2007) allowed open-label TMS reintroduction for symptom re-emergence to augment maintenance antidepressant monotherapy over a 24-week period in responders during the first or second study. The authors determined that TMS was administered in over 10,000 cumulative treatment sessions in the study program, with no deaths or seizures. Most adverse events were mild to moderate in intensity. Transient headaches and scalp discomfort were the most common adverse events. Auditory threshold and cognitive function did not change. There was a 4.5% discontinuation rate due to adverse events during acute treatment.

****Additional reviewed studies listed in References***

Systematic Reviews/Meta-Analyses

Brunoni and colleagues (2017) conducted a systematic review and meta-analysis of eighty-one randomized controlled trials (RCTs) that compared any rTMS intervention with sham or another rTMS intervention. Those trials performing less than 10 sessions of rTMS were excluded. The total sample size for the analysis was 4,233 patients. The authors note that most studies presented an unclear risk of bias, mainly owing to blinding inadequacy. They concluded that differences in clinical efficacy and acceptability between rTMS modalities might exist, but could not be confirmed from the available data. Novel rTMS interventions were not found to be more effective than sham; the authors note that these interventions were insufficiently investigated and warrant more controlled studies to determine their efficacy.

Allan and colleagues (2011) conducted a meta-analysis of thirty-one studies on TMS for the treatment of depression. This provided a cumulative sample of 815 active and 716 sham TMS courses. Studies were included if they had a randomized parallel or cross-over design with sham control, both patients and investigators were unaware of the treatment conditions, samples consisted of > 10 patients in each group, participants in each treatment group had a diagnosis of major depressive episode, and the outcome was measured using a version of the HDRS or MADRS with baseline and follow-up scores. The authors found a moderately sized effect in favor of TMS, with a significant variability between study effect sizes. At 4 weeks' follow-up after TMS, the authors noted no further change in depression severity. The authors conclude that if the TMS effect is specific, only further large double-blind randomized controlled designs with systematic exploration of treatment and patient parameters will help to define optimum treatment indications and regimen.

Slotema and colleagues (2010) conducted a meta-analysis on the efficacy of rTMS in psychiatric disorders. A total of 57 TMS studies were selected for the meta-analysis, including diagnoses of depression (40 studies), auditory verbal hallucinations (AVH; 7 studies), negative symptoms of schizophrenia (7 studies), and obsessive-compulsive disorder (3 studies). Other diagnoses provided too small of a sample size to be included in the meta-analysis. The studies specific to depression were divided into (1) rTMS vs. sham (34 studies), and (2) rTMS vs. ECT (6 studies). The meta-analysis indicated that rTMS is more effective than sham treatment in the treatment of depression, and a trend that rTMS as a monotherapy was more effective than as an adjunctive treatment to priorly started antidepressants. Further analysis showed that ECT yielded more favorable results than rTMS. The authors note that the duration of effect using rTMS in the treatment of depression is unknown.

Schutter (2009) conducted a meta-analysis to study the antidepressant effects of rTMS in all available published clinical trials that applied at least five treatment sessions of high-frequency rTMS in double-blind sham-controlled designs. A total of thirty studies (n = 1164 patients) that compared change in depression score from baseline to endpoint of active rTMS (n = 606) vs. sham rTMS (n = 558) treatment were included. Among them, a total of 850 (73%) patients were considered resistant to medication. The meta-analysis findings showed that high-frequency TMS was found to be superior to sham in the treatment of depression. TMS was also found to be a safe method that was well tolerated by patients. The author cautions that integrity of blinding and a lack of proper control conditions are considered limitations of rTMS trials. The meta-analysis concludes that rTMS may be an alternative for patients with major depression, and in particular, those who are unable to tolerate antidepressant medication side effects.

Other Reports

An indirect analysis by Demitrack & Thase (2009) provided a comparison of outcomes observed within the treatment cohort of the O'Reardon, et al (2007) study to those with similar clinical endpoints as reported in other datasets from the published literature of antidepressant medications. The authors determined that the efficacy of TMS demonstrated in randomized controlled trials was comparable to that of pharmaceutical antidepressants studied in similarly designed registration trials. No head-to-head trials between TMS and antidepressant medications were included in the analysis.

AHRO Reports

The AHRQ (Gaynes, et al 2011) conducted a Comparative Effectiveness Review of Nonpharmacologic Interventions for Treatment Resistant Depression, focused primarily on Tier 1 studies - defined as those studies of patients that have two or more antidepressant medication (ADM) failures. In addition, the review looked at lower tier studies (defined as one or more ADM failures or that didn't include number of failures as a variable in analyses). The report concluded that there was limited direct evidence for rTMS (where rTMS was compared head-to-head to other available treatments). Among Tier 1 studies, two "fair" trials were identified: one that compared ECT and rTMS, and one that compared ECT and ECT plus rTMS. The conclusion was that studies had "low strength of evidence". No differences between treatment conditions were found for depressive severity, response rates, and remission rates between ECT and rTMS. There was no evidence of comparative effectiveness compared to any other treatments. When combining Tier 1 studies with lower tier studies, evidence for rTMS efficacy compared to ECT was mixed. The studies had differential intervention methodologies and possible overlap in populations across studies, making comparisons across the various tiers difficult. The strength of the indirect evidence for rTMS (examining comparisons between treatment and sham) concluded that there was evidence for greater effectiveness of rTMS versus sham in Tier 1 studies. rTMS was beneficial relative to controls receiving a sham procedure on severity of depressive symptoms, response rate, and remission rate outcomes. rTMS produced a greater decrease in depressive severity; response rates were greater with rTMS than sham - those receiving rTMS were more than three times as likely to achieve a depressive response as patients receiving a sham procedure.

As part of a previously published comparative effectiveness review on nonpharmacologic interventions for patients with treatment-resistant depression (Gaynes, et al 2011), the AHRQ (Gaynes, et al 2014) reviewed evidence addressing the efficacy of rTMS compared with sham control. The authors selected randomized controlled trials comparing rTMS with sham. The core patient population of interest was patients with major depressive disorder (MDD) who met the defined criteria of treatment-resistant depression as 2 or more treatment failures, though many trials did not use this definition when formulating their inclusion criteria. In total, 35 published articles reporting on 27 trials were included. Of the trials, 18 were labeled as "Tier 1 evidence" (evaluation of outcomes in a treatment-resistant population), with sample sizes ranging from 12 to 74 subjects and study duration ranging from 1 week to 6 weeks. Seven of the trials reported the mean number of antidepressant treatment failures (with a range of 3.2 - 6.5 failures). Results found rTMS to be beneficial compared to sham treatment, averaging a clinically meaningful decrease on the HDRS of more than 4 points when compared to sham. Limited evidence and variable treatment parameters prevented conclusions about which specific treatment options are more effective than others. How long these benefits persist also remained unclear. The authors conclude that for MDD patients with antidepressant treatment failure, rTMS is a reasonable, effective consideration.

Professional Societies

American Psychiatric Association (APA): In a 2010 clinical practice guideline for the treatment of patients with major depressive disorder, the APA states that electroconvulsive therapy (ECT) remains the treatment of best established efficacy against which other stimulation treatments (e.g., vagus nerve stimulation, deep brain stimulation, transcranial magnetic stimulation, other electromagnetic stimulation therapies) should be compared. For patients whose symptoms have not responded adequately to medication, ECT remains the most effective form of therapy and should be considered [I]. [For these patients] Magnetic stimulation could also be considered [II]. According to the APA, a substantial number of studies of TMS have been conducted, but most have had small sample sizes, and the studies overall have yielded heterogeneous results. Further complicating the interpretation of the TMS literature is the variability in stimulation intensities (relative to the motor threshold), stimulus parameters (e.g., pulses/second, pulses/session), anatomical localization of stimulation, and number of TMS sessions in the treatment course.

The three APA rating categories represent varying levels of clinical confidence:

- I: Recommended with substantial clinical confidence
- II: Recommended with moderate clinical confidence
- III: May be recommended on the basis of individual circumstances

Clinical TMS Society: In their 2016 consensus review and treatment recommendations for TMS therapy for major depressive disorder, the Clinical TMS Society systematically reviewed the peer-reviewed literature on TMS therapy. In total, over 100 publications were identified, reviewed, and graded on their strength of evidence. When the current published evidence was seen as incomplete or insufficient, expert opinion was included where available. The results of the review recommend that left prefrontal rTMS repeated daily for 4-6 weeks is an effective and safe treatment for depression in patients who are treatment resistant or intolerant (Perera et al 2016).

World Federation of Societies of Biological Psychiatry (WFSBP): In their 2015 guidelines for biological treatment of unipolar depressive disorders, the WFSBP notes that antidepressant effects [of rTMS] “have now been confirmed in several large-scale clinical trials and a number of meta-analyses.” The guidelines additionally state that “maintenance rTMS for depression has only been explored very rarely. To date there are no sham-controlled studies supporting its efficacy” (Bauer et al 2015).

U.S. FOOD AND DRUG ADMINISTRATION

Transcranial Magnetic Stimulation must be administered by an FDA-cleared device and utilized in accordance with the FDA-labeled indications.

To date, the FDA has only cleared TMS devices for the treatment of major depressive disorder. While TMS may be the preferred choice over ECT for some patients, ECT remains the stimulation treatment of best established efficacy, against which other stimulations treatments should be compared (American Psychiatric Association, 2010). Currently, the efficacy of maintenance TMS therapy is not supported by evidence from controlled clinical trials.

CENTERS FOR MEDICARE AND MEDICAID SERVICES

- LCD ID: L33398 (CT, IL, MA, ME, MN, NH, NY, RI, VT) – Contractor Name: National Government Services, Inc.
- LCD ID: L34269 (AL, GA, TN) – Contractor Name: Cahaba Government Benefit Administrators, LLC
- LCD ID: L34522 (FL, Puerto Rico, Virgin Islands) – Contractor Name: First Coast Service Options, Inc.
- LCD ID: L34641 (IA, IN, KS, MI, MO, NE) – Contractor Name: Wisconsin Physicians Service Insurance Corporation
- LCD ID: L34869 (NC, SC, VA, WV) – Contractor Name: Palmetto GBA
- LCD ID: L34998 (AR, CO, DC, DE, LA, MD, MS, NJ, NM, OK, PA, TX) – Contractor Name: Novitas Solutions, Inc.
- LCD ID: L36469 (KY, OH) – Contractor Name: CGS Administrators, LLC

APPLICABLE CODES

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member-specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Coverage Determination Guidelines may apply.

CPT Code	Description
90867	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; initial, including cortical mapping, motor threshold determination, delivery and management
90868	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent delivery and management, per session
90869	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent motor threshold re-determination with delivery and management

CPT® is a registered trademark of the American Medical Association

ICD-10 Diagnosis Code	ICD-10 Description
F32.2	Major depressive disorder, single episode, severe without psychotic features
F32.3	Major depressive disorder, single episode, severe with psychotic features
F33.2	Major depressive disorder, recurrent severe without psychotic features
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms

REFERENCES

- Allan CL, Herrmann LL, & Ebmeier KP. Transcranial magnetic stimulation in the management of mood disorders. *Neuropsychobiology* 2011; 64:163-169.
- American Psychiatric Association. *Diagnostic and statistical manual of mental disorders*, 5th Edition. Arlington, VA: American Psychiatric Publishing; 2013.
- American Psychiatric Association. *Practice guidelines for the treatment of patients with major depressive disorder*, 3rd Edition. Arlington (VA): American Psychiatric Publishing; 2010 Oct.
- American Psychiatric Association. *Practice guidelines for the psychiatric evaluation of adults*, 3rd Edition. Arlington, VA: American Psychiatric Publishing; 2016.
- Avery DH, Holtzheimer PE, Fawaz W, Russo J, Neumaier J, Dunner DL, . . .Roy-Byrne, P. A controlled study of repetitive transcranial magnetic stimulation in medication-resistant major depression. *Biological Psychiatry* 2006; 59:187-194.
- Avery DH, Isenberg KE, Sampson SM, Janicak PG, Lisanby SH, Maixner DF, . . .George MS. Transcranial magnetic stimulation in the acute treatment of major depressive disorder: Clinical response in an open-label extension trial. *Journal of Clinical Psychiatry* 2008; 69(3):441-451.
- Bauer M, Severus E, Kohler S, Whybrow PC, Angst J, & Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: Maintenance treatment of major depressive disorder-update 2015. *The World Journal of Biological Psychiatry* 2015; 16:76-95.
- Brunoni AR, Chalmani A, Moffa AH, Razza LB, Gattaz WF, Daskalakis ZJ, & Carvalho AF. Repetitive transcranial magnetic stimulation for the acute treatment of major depressive episodes: A systematic review with network meta-analysis. *JAMA Psychiatry* 2017; 74(2):143-152.
- Carpenter LL, Janicak PG, Aaronson ST, Boyadjis T, Brock DG, Cook IA, Demitrack MA. Transcranial magnetic stimulation (TMS) for major depression: A multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. *Depression and Anxiety* 2012; 29(7):587-596.
- Cusin, C., Yang, H., Yeung, A., & Fava, M. Rating scales for depression. In L.Baer & M.A. Blais (eds.), *Handbook of Clinical Rating Scales and Assessment in Psychiatry and Mental Health* 2010. New York: Humana Press.
- Demitrack MA, & Thase ME. Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: Synthesis of recent data. *Psychopharmacology Bulletin* 2009; 42(2):5-38.
- Dunner DL, Aaronson ST, Sackeim HA, Janicak PG, Carpenter LL, Boyadjis T, . . .Demitrack MA. A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: Durability of benefit over a 1-year follow-up period. *Journal of Clinical Psychiatry* 2014; 75(12):1394-1401.
- Fitzgerald PB, Benitez J, de Castella A, Daskalakis J, Brown TL, & Kulkarni J. A randomized, controlled trial of sequential bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression. *American Journal of Psychiatry* 2006; 163(1):88-94.
- Fitzgerald PB, Brown TL, Marston NA, Daskalakis ZJ, de Castella A, & Kulkarni J. Transcranial magnetic stimulation in the treatment of depression: A double-blind, placebo-controlled trial. *Archives of General Psychiatry* 2003; 60: 1002-1008.
- Gaynes BN, Lloyd SW, Lux L, Gartlehner G, Hansen RA, Brode S, . . .Lohr KN. Repetitive transcranial magnetic stimulation for treatment-resistant depression: A systematic review and meta-analysis. *Journal of Clinical Psychiatry* 2014; 75(5):477-489.
- Gaynes BN, Lux L, Lloyd S, Hansen RA, Gartlehner G, Thieda P, . . .Lohr KN. Nonpharmacologic Interventions for Treatment-Resistant Depression in Adults. Comparative Effectiveness Review No. 33. (Prepared by RTI International-University of North Carolina (RTI-UNC) Evidence-based Practice Center under Contract No. 290-02-00171.) AHRQ Publication No. 11-EHC056-EF. Rockville, MD: Agency for Healthcare Research and Quality. September 2011.
- George MS, Lisanby SH, Avery D, McDonald WM, Durkalski V, Pavlicova M, Anderson B, Nahas Z, Bulow P, Zarkowski P, Holtzheimer PE, Schwartz T, & Sackeim HA. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: A sham-controlled randomized trial. *Arch Gen Psychiatry* 2010; 67(5):507-516.
- Haesebaert F, Moirand R, Schott-Pethelaz AM, Brunelin J, & Poulet E. Usefulness of repetitive transcranial magnetic stimulation as a maintenance treatment in patients with major depression. *The World Journal of Biological Psychiatry* 2016; doi:10.1080/15622975.2016.1255353

- Harel EV, Rabany L, Deutsch L, Bloch Y, Zangen A, & Levkovitz Y. H-coil repetitive transcranial magnetic stimulation for treatment resistant major depressive disorder: An 18-week continuation safety and feasibility study. *The World Journal of Biological Psychiatry* 2014; 15(4):298-306.
- Isserles M, Rosenberg O, Dannon P, Levkovitz Y, Kotler M, Deutsch F, Lerer B, & Zangen A. Cognitive-emotional reactivation during deep transcranial magnetic stimulation over the prefrontal cortex of depressive patients affects antidepressant outcome. *Journal of Affective Disorders* 2011; 128:235-242.
- Janicak PG, Nahas Z, Lisanby SH, Solvason HB, Sampson SM, McDonald WM, . . .Schatzberg AF. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: Assessment of relapse during a 6-month, multisite, open-label study. *Brain Stimulation* 2010; 3:187-199.
- Janicak PG, O'Reardon JP, Sampson SM, Husain MM, Lisanby SH, Rado JT, . . .Demitrack MA. Transcranial magnetic stimulation in the treatment of major depressive disorder: A comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. *Journal of Clinical Psychiatry* 2008; 69(2):222-232.
- Levkovitz Y, Isserles M, Padberg F, Lisanby SH, Bystritsky A, Xia G, . . .Zangen A. Efficacy and safety of deep transcranial magnetic stimulation for major depression. A prospective, multi-center, randomized, controlled trial. *World Psychiatry* 2015; 14:64-73.
- Mantovani A, Pavlicova M, Avery D, Nahas Z, McDonald WM, Wajdik CD, . . .Lisanby SH. Long-term efficacy of repeated daily prefrontal transcranial magnetic stimulation (TMS) in treatment-resistant depression. *Depression and Anxiety* 2012; 29:883-890.
- McClintock SM, Reti IM, Carpenter LL, McDonald WM, Dubin M, Taylor SF, . . . Lisanby SH. Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression. *J Clin Psychiatry*. 2017 May 23.
- McDonald WM, Durkalski V, Ball ER, Holtzheimer PE, Pavlicova M, Lisanby SH, . . .George MS. Improving the antidepressant efficacy of transcranial magnetic stimulation: Maximizing the number of stimulations and treatment location in treatment-resistant depression. *Depression and Anxiety* 2011; 28(11):973-980.
- O'Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, . . .Sackeim HA. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: A multisite randomized controlled trial. *Biological Psychiatry* 2007; 62:1208-1216.
- Perera T, George MS, Grammer G, Janicak PG, Pascua-Leone A, & Wirecki TS. The Clinical TMS Society consensus review and treatment recommendations for TMS therapy for major depressive disorder. *Brain Stimulation* 2016; 9:336-346.
- Philip NS, Dunner DL, Dowd SM, Aaronson ST, Brock DG, Carpenter LL, & George MS. Can medication free, treatment-resistant depressed patients who initially respond to TMS be maintained off medications? A prospective, 12-month multisite randomized pilot study. *Brain Stimulation* 2016; 9:251-257.
- Schutter DJ. Antidepressant efficacy of high-frequency transcranial magnetic stimulation over the left dorsolateral prefrontal cortex in double-blind sham-controlled designs: A meta-analysis. *Psychological Medicine* 2009; 39:65-75.
- Slotema CW, Blom JD, Hoek HW, & Sommer IE. Should we expand the toolbox of psychiatric treatment methods to include repetitive transcranial magnetic stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. *Journal of Clinical Psychiatry* 2010; 71(7):873-884.
- U.S. Food and Drug Administration. Pediatric Medical Devices 2017. Retrieved from: <http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ucm135104.htm>
- U.S. Food and Drug Administration. 510(K) Summary: Rapid2 Therapy System 2015. 510(K) Number K143531. Retrieved from: http://www.accessdata.fda.gov/cdrh_docs/pdf14/K143531.pdf
- U.S. Food and Drug Administration. 510(K) Summary: MagVita TMS Therapy System 2015. 510(K) Number K150641. Retrieved from: http://www.accessdata.fda.gov/cdrh_docs/pdf15/K150641.pdf
- U.S. Food and Drug Administration. 510(K) Summary: Brainsway Deep TMS System 2013. 510(K) Number K122288. Retrieved from: http://www.accessdata.fda.gov/cdrh_docs/pdf12/k122288.pdf
- U.S. Food and Drug Administration. 510(K) Summary: NeuroStar TMS Therapy System 2014. 510(K) Number K133408. Retrieved from: <https://neurostar.com/pdf/FDA%20Clearance%20TMS%20All%20Dates.pdf>
- U.S. Food and Drug Administration. 510(K) Summary: NeuroStar TMS Therapy System. 510(K) Number K083538. Retrieved from: http://www.accessdata.fda.gov/cdrh_docs/pdf8/K083538.pdf

HISTORY/REVISION INFORMATION

Date	Action/Description
06/13/2017	<ul style="list-style-type: none">• New Policy
11/16/2017	<ul style="list-style-type: none">• Policy revision: Added language to indicate that treatment is for patients 18 years of age and older, updated language surrounding provider supervision, changed Utilization Management to 30 sessions plus 6 taper, updates to template.